Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SFCC provides outsourced drug development research services -- Ignore unavailable to you. Want to Upgrade?

To: SI Bob who wrote (19)	1/10/2006 9:31:13 AM
From: SI Bob	Read Replies (4) \| Respond to of 29

Cute. Latest PR puts a lot of verbage into how one guy's job is gonna change and practically whispers "SEC inquiry" as an aside. I'm bailing. I'm just glad I sold some afterhours yesterday hoping to be able to buy some extra-cheap ELN, which I wasn't. On Scottrade, you can only trade Nas stocks in afterhours.

To: SI Bob who wrote (19)	1/27/2006 11:28:15 AM
From: Skywatcher	Respond to of 29

From FORBES Losers? Drug tester SFBC International (nasdaq: SFCC - news - people ), which ranked 11th on our 2005 Fastest-Growing Technology list, fell 51% over the past 12 months. SFBC stirred up controversy with some of its drug-testing practices, and, as a result, they are responding to an informal Securities and Exchange Commission inquiry along with a number of class-action suits from investors. SFBC has rejected the allegations based on the findings of its independent counsel review, which it forwarded to the Senate Finance Committee as requested by Sen. Charles Grassley. But the company recently changed top management. Although SFBC’s $362 million in trailing-12 month revenue shows a 152% year-over-year increase, its current difficulties and strong drop in share price kept it off of this year’s Fast Tech list.